ライフサイエンスコーパス: vaccine recipient

1 , urine, or saliva samples obtained from any vaccine recipient.

2 ere within the range observed in human RTS,S vaccine recipients.

3 iating nonclonally related antibodies from 6 vaccine recipients.

4 erum antibody levels) was detected in 70% of vaccine recipients.

5 an HIV-1 RNA level over time was lower among vaccine recipients.

6 iclovir treatment (p=0.0287) were reduced in vaccine recipients.

7 5; 95% CI, 0.24-0.51) were less likely among vaccine recipients.

8 it should be translated into adulthood among vaccine recipients.

9 related to sexual activity among adolescent vaccine recipients.

10 or adverse reproductive health effects among vaccine recipients.

11 of 75-microg vaccine, and 77% of 135-microg vaccine recipients.

12 of 75-microg vaccine, and 92% of 135-microg vaccine recipients.

13 l, and antibody responses in the majority of vaccine recipients.

14 jected 1 intussusception event/38,000-59,000 vaccine recipients.

15 pneumococcal disease within populations and vaccine recipients.

16 growth in cell cultures and the organisms of vaccine recipients.

17 cinia virus from vaccination sites of Dryvax vaccine recipients.

18 ty was unchanged for about half of the adult vaccine recipients.

19 nd D antigens in a significant proportion of vaccine recipients.

20 rs and causes reactogenicity in up to 30% of vaccine recipients.

21 r mild diarrhea occurred in six (22%) of the vaccine recipients.

22 rative responses (LPRs) developed in <30% of vaccine recipients.

23 lative resistance to HIV-1 as well as in HIV vaccine recipients.

24 /42) of placebo recipients and 3% (7/210) of vaccine recipients.

25 ects reduce the risk of reactive diarrhea in vaccine recipients.

26 equency of arthritis or neurologic events in vaccine recipients.

27 safety for laboratory workers and potential vaccine recipients.

28 ry low rate, they can cause poliomyelitis in vaccine recipients.

29 responses against gp120 were induced in all vaccine recipients.

30 ctivity in convalescent individuals and mRNA vaccine recipients.

31 he long-interval and short-interval BNT162b2 vaccine recipients.

32 considerably lower than that among BNT162b2 vaccine recipients.

33 ndesired inflammatory responses and fever in vaccine recipients.

34 se were measured in infected and noninfected vaccine recipients.

35 Syn epitope hotspots were observed in 85% of vaccine recipients.

36 ased spike-specific CD8+ T cells in the mRNA vaccine recipients.

37 ns can engage with the host immune system of vaccine recipients.

38 helper cell responses in the LN of both mRNA vaccine recipients.

39 47 vaccinees to that of seronegative gB/MF59 vaccine recipients.

40 nts in two cohorts (<50 and >55 age) of mRNA vaccine recipients.

41 ll bystander activation in a cohort of human vaccine recipients.

42 YFV-vaccine recipients but not in primed VZV-vaccine recipients.

43 antibody levels for up to 12 years for most vaccine recipients.

44 and antibody responses were detected in all vaccine recipients.

45 A single dose was immunogenic in almost all vaccine recipients.

46 id not differ significantly between ID vs IM vaccine recipients.

47 ific Tfh cells were increased in RV144 trial vaccine recipients.

48 The LTPS enrolled 6867 SPS vaccine recipients.

49 e increased rate of HIV-1 infections seen in vaccine recipients.

50 and unexpected excess HIV infections in the vaccine recipients.

51 trations persisted in > or =85% of conjugate-vaccine recipients 104 weeks later.

52 Of 39 vaccine recipients, 13 were protected and 26 were not.

53 vaccine recipients, 17 HIV-1-infected rgp120 vaccine recipients, 15 HIV-1-infected placebo recipients

54 edian follow-up of 42 months (IQR 31-42), 63 vaccine recipients (16%) had HIV-1 infection compared wi

55 eumoniae density was substantially higher in vaccine recipients (16,687 vs. 1935 gene copies per mill

56 te vaccine recipients than in polysaccharide vaccine recipients (16.66 microg/mL vs. 8.31 microgm/mL;

57 e were evaluated in 19 HIV-1-infected rgp160 vaccine recipients, 17 HIV-1-infected rgp120 vaccine rec

58 either the primary end points (22/3528 V710 vaccine recipients [2.6 per 100 person-years] vs 27/3517

59 Twenty-three placebo recipients (49%) and 16 vaccine recipients (29%) reported respiratory symptoms (

60 e first 14 days after vaccination (1219/3958 vaccine recipients [30.8%; 95% CI, 29.4%-32.3%] and 866/

61 e significantly less frequent in bivalent ca vaccine recipients (31%) than in monovalent ca H1N1 reci

62 otal of 620 456 AE reports (mean [SD] age of vaccine recipients, 51.8 [17.6] years; 435 797 reports f

63 ventable, of whom 38 677 (25%) were two-dose vaccine recipients, 74 438 (48%) were too young to recei

64 iters were significantly higher in conjugate vaccine recipients (755.6 vs 37.6 for group A, P<.001; 3

65 olicited local adverse event, reported by 28 vaccine recipients (93%) and two placebo recipients (33%

66 A higher proportion of previous alphavirus vaccine recipients (93.3% [95% CI 78.7-98.2]) had a four

67 nation, 93% (n=139/149) to 100% (n=48/48) of vaccine recipients achieved protective hSBA titres equal

68 Follow-up of vaccine recipients acquiring HSV-2 infection showed vacc

69 ralizing antibodies were detected in 100% of vaccine recipients after a single immunization.

70 Transient rVSV viremia was noted in all the vaccine recipients after dose 1.

71 nism explaining the excess HIV infections in vaccine recipients after rAd5-HIV vaccination and highli

72 8 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild-type, Delta, and Omicron

73 sions in high-dose compared to standard-dose vaccine recipients, an outcome not shown in randomised s

74 e were compared over 692,819 person-years in vaccine recipients and 1,534,280 person-years in vaccine

75 24 (0.3%) cases occurred among 8471 vaccine recipients and 106 (1.2%) among 8502 placebo rec

76 After inoculation, 255 (1.4%) vaccine recipients and 254 (1.4%) placebo recipients rep

77 isation showed no difference between the 287 vaccine recipients and 281 placebo recipients in rate of

78 ited reports of grade 3 symptoms in 17.0% of vaccine recipients and 3.2% of placebo recipients.

79 .0 years [IQR 13.5]), 30 previous alphavirus vaccine recipients and 30 alphavirus vaccine-naive contr

80 ite side effects were reported by 1604 (48%) vaccine recipients and 539 (16%) placebo recipients in t

81 confirmed cases of herpes zoster (315 among vaccine recipients and 642 among placebo recipients) and

82 e second year, after the third injection, 16 vaccine recipients and 66 placebo recipients contracted

83 07 cases of postherpetic neuralgia (27 among vaccine recipients and 80 among placebo recipients) were

84 ained, over an 18-month period, from 101 ACP-vaccine recipients and 99 control subjects, to assess AC

85 GMTs peaked in previous alphavirus vaccine recipients and alphavirus vaccine-naive controls

86 There was no significant difference between vaccine recipients and control groups in incidence of HI

87 demographically balanced cohorts of BNT162b2 vaccine recipients and COVID-19 patients, from which we

88 s were available for 109 of the seronegative vaccine recipients and for 110 of the seronegative place

89 tent but risk causing adenovirus diseases in vaccine recipients and health care workers.

90 n 22 of 1328 (6.7 per 1000 person-years) VZV vaccine recipients and in 61 of 1350 (18.5 per 1000 pers

91 adverse events were reported by eight (27%) vaccine recipients and no placebo recipients; the most c

92 analyzed cytokine responses in both primary vaccine recipients and revaccinated subjects every other

93 pA ELISA to assess the antibody responses of vaccine recipients and subjects with Lyme disease.

94 r time has the same profile for the original vaccine recipients and the original placebo recipients a

95 tude and duration of the boost in VZV-CMI in vaccine recipients and the relationship of this boost to

96 cited adverse events were reported by 44% of vaccine recipients and were transient and mild or modera

97 in placebo recipients (compared with zoster vaccine recipients) and in older individuals.

98 Env responses predominated (19 of 30; 63% of vaccine recipients) and were mediated by polyfunctional

99 Haemophilus influenza meningitis (1% rabies-vaccine recipients), and one case of tuberculosis (1% RT

100 hL3, which produced acute febrile illness in vaccine recipients, and DENV-2 PDK53, which has a good c

101 rum samples from HIV-infected donors, VAX004 vaccine recipients, and healthy HIV-negative subjects us

102 m samples from 80%-90% of bivalent conjugate vaccine recipients, and these responses were similar to

103 reased HIV-1 infection rates in subgroups of vaccine recipients are being explored.

104 activation were also increased in mRNA-1273 vaccine recipients as compared to BNT162b2 recipients.

105 ve examined serum cytokine levels in primary vaccine recipients at 1 and 3-5 weeks after vaccination

106 uantification were shown in 37% (n=18/49) of vaccine recipients at 6 months, in 29% (n=14/48) at 12 m

107 V antibodies were significantly increased in vaccine recipients at 6 weeks after vaccination.

108 4 months of age was investigated by boosting vaccine recipients at age 13-16 months or 4 years with 1

109 5 antibody titre 200 or less, 24 (3%) of 741 vaccine recipients became HIV-1 infected versus 21 (3%)

110 titate 108 serum cytokines and chemokines in vaccine recipients before and 1 week after primary immun

111 The potential for vaccine recipients being misclassified as HIV infected i

112 e similar to those previously reported among vaccine recipients between the ages of 18 and 55 years a

113 IgG responses were significantly lower among vaccine recipients boosted at month 12 (pooled groups 2

114 design that measures the markers from all 12 vaccine recipient breakthrough COVID-19 cases starting 7

115 early IFN-associated responses in naive YFV-vaccine recipients but not in primed VZV-vaccine recipie

116 ), 90% of placebo and 87% of live attenuated vaccine recipients but only 23% of inactivated vaccine r

117 the injection site were more frequent among vaccine recipients but were generally mild.

118 an immunodeficiency virus (HIV) type 1 gp120 vaccine recipients by age, sex, and race.

119 a virus-infected patients and from influenza vaccine recipients by complement-dependent lysis (CDL) a

120 dy responses were detected in 15 (50%) of 30 vaccine recipients by enzyme-linked immunosorbant assay

121 ytokine staining assay and in 22 (73%) of 30 vaccine recipients by enzyme-linked immunospot assay.

122 immunosorbant assay and in 28 (93.3%) of 30 vaccine recipients by immunoprecipitation followed by We

123 ence, the time period over which an infected vaccine recipient can transmit to susceptible sex partne

124 iting, diarrhea, or behavioral changes among vaccine recipients, compared with placebo recipients, du

125 and duration of symptoms observed in primary vaccine recipients, compared with revaccinated subjects,

126 vaccine trial, was 22-fold higher in Chiron vaccine recipients, compared with RV144 vaccinees.

127 HIV-specific T cell lines obtained from vaccine recipients confirmed V2 specificity, polyfunctio

128 A total of 325,715 COVID-19 vaccine recipients (CoronaVac: 167,337; BNT162b2: 158,37

129 years; 435 797 reports from women [70.2%]; a vaccine recipient could potentially file more than 1 rep

130 ccine recipients but only 23% of inactivated vaccine recipients demonstrated serologic confirmation o

131 he pathogen Borrelia burgdorferi, and 95% of vaccine recipients develop substantial titers of antibod

132 tive placebo recipients; 84% of seronegative vaccine recipients developed a > or =4-fold increase in

133 Vaccine recipients developed lymphoproliferative respons

134 logic category, at least 79% of HIV-infected vaccine recipients developed VZV-specific antibody and/o

135 0) (P for interaction = .006), while 1.7% of vaccine recipients died of cardiovascular causes compare

136 ients and four (4.0%, 1.1-9.8) of 101 rabies-vaccine recipients died, but no deaths were deemed relat

137 ite a trend favoring viral suppression among vaccine recipients, differences in HIV-1 RNA levels did

138 when it is administered alone, up to 14% of vaccine recipients do not achieve protective levels of a

139 atal animals were not considered as suitable vaccine recipients either because of immune immaturity o

140 Eleven vaccine recipients exhibited delayed onset of parasitemi

141 As a group, vaccine recipients experienced more injection-site react

142 monia (1% RTS,S/AS01 recipients vs 3% rabies-vaccine recipients), five cases of gastroenteritis (3% R

143 ritis (3% RTS,S/AS01 recipients vs 2% rabies-vaccine recipients), five cases of malnutrition (2% RTS,

144 en to further assess vaccine efficacy in SPS vaccine recipients followed for up to 11 years postvacci

145 nt infectivity and immunogenicity and primed vaccine recipients for anamnestic responses, encouraging

146 re detected in 28 (93.3%) and 18 (60%) of 30 vaccine recipients for CD4(+) and CD8(+) T cells, respec

147 3 HI titers, and that bPIV3 vaccine prevents vaccine recipients from developing antibody profiles of

148 Per-protocol cohorts included vaccine recipients from HVTN 100 (n = 186, 60% male, med

149 In infants of GBS vaccine recipients, GBS serotype-specific antibody geome

150 Twenty percent of vaccine recipients generated detectable cytolytic respon

151 Following seroconversion to CHIKV, CHIKV vaccine recipients' geometric mean titers (GMTs) to VEEV

152 Seventy-eight percent of HSV1-/HSV2- vaccine recipients had a >=4-fold increase in neutralizi

153 Protected vaccine recipients had a higher CSP-specific IgG titer (

154 ter 3 doses of vaccine was.84; however, more vaccine recipients had an elevated ELISA titer paired wi

155 ients and 12 (11.9%, 6.3-19.8) of 101 rabies-vaccine recipients had at least one serious adverse even

156 resurgence, approximately 16% of first-dose vaccine recipients had completed their second dose.

157 Chiron vaccine recipients had higher and more-durable IgG respo

158 In total, 16, 19, and 15 vaccine recipients had increases after 1, 2, and 3 doses

159 Ten placebo recipients but no vaccine recipients had laboratory-confirmed symptomatic

160 Primary vaccine recipients had maximal levels of granulocyte-col

161 All vaccine recipients had positive HPV-11 VLP-specific lymp

162 By day 28, all the vaccine recipients had seroconversion as assessed by an

163 By day 57, 52 (92%) of vaccine recipients had seroconverted (microneutralisatio

164 ntrol subjects and 3 (1.7%) of 180 influenza vaccine recipients had serologic evidence of influenza t

165 All vaccine recipients had specific IgG detectable 21 days p

166 ty complex class I allelic expression by the vaccine recipient in determining the relative breadth of

167 ponse of patients recovered from COVID-19 or vaccine recipients in a cell-free assay system.

168 At rechallenge, 4 of 9 vaccine recipients in each group were still completely p

169 nt interdose intervals among >6 million mRNA vaccine recipients in Georgia, USA, from December 2020 t

170 os are higher in infected than in uninfected vaccine recipients in RV144.

171 y of Fc-mediated Ab effector responses among vaccine recipients in the VAX004 trial and in HIV-infect

172 ial revealed increased mortality rates among vaccine recipients in whom postsurgical S. aureus infect

173 in 75% (267) of the 25% random sample of all vaccine recipients (including both low and high Ad5 anti

174 y strong and were present in the majority of vaccine recipients, including a strong response against

175 ntibody levels increased significantly among vaccine recipients, including responses competitive with

176 h of HIV-specific CD8(+) T cell responses in vaccine recipients, independent of type-specific preexis

177 The increased risk of HIV-1 acquisition in vaccine recipients, irrespective of number of doses rece

178 ion is leaky (ie, the susceptibility of each vaccine recipient is reduced by a factor that is equal t

179 The induction of VISP in HIV vaccine recipients is common, especially with vaccines c

180 how this affects the antibody repertoire of vaccine recipients is inadequate.

181 mmunodominance in uninfected, HLA-A*0201 HIV vaccine recipients is similar to that seen in chronicall

182 oliovirus vaccine (OPV) in the intestines of vaccine recipients leads to reversions that increase vir

183 -tFliC MNP boosting immunization to seasonal vaccine recipients may be a rapid approach for increasin

184 e slightly higher rates of hepatitis A among vaccine recipients may indicate a true modest difference

185 Increased rates of pneumococcal disease in vaccine recipients may necessitate a reappraisal of this

186 onses solely from blood mononuclear cells of vaccine recipients may not suffice to compare the potenc

187 th vaccine formulation and dietary status of vaccine recipients may significantly affect the efficacy

188 jected 1 intussusception event/11,000-16,000 vaccine recipients; modeling of a 2-dose schedule beginn

189 Only 1 of 42 vaccine recipients mounted a transient LCMV vector-neutr

190 Most vaccine recipients mounted potent neutralizing antibody

191 In 2 settings, 0.5% and 3.0% of vaccine recipients needed short-term sick leave.

192 nosorbent assay (ELISA) antibody and, for gB-vaccine recipients, neutralizing antibody.

193 Among 4 746 518 vaccine recipients, no excess risk of immune thrombocyto

194 Among vaccine recipients, no important reduction in the number

195 days post antibody measurement and from 639 vaccine recipient non-cases.

196 Finally, neither vaccine recipients nor those challenged with the wild-ty

197 was 44% (95% CI 31-55); all but one case in vaccine recipients occurred in women infected with HPV16

198 Among 34 HIV vaccine recipients of live canarypox vector expressing m

199 e recipients), one case of sepsis (1% rabies-vaccine recipients), one case of Haemophilus influenza m

200 ition (2% RTS,S/AS01 recipients vs 3% rabies-vaccine recipients), one case of sepsis (1% rabies-vacci

201 V-1 infection risk in the CT- or TT-carrying vaccine recipients only.

202 r and more-durable IgG responses than VaxGen vaccine recipients or ALVAC/AIDSVAX vaccinees, with vacc

203 ack Ag-specific plasmablast responses in HIV-vaccine recipients over a period of 42 d and performed a

204 ring in 69% of placebo recipients vs. 37% of vaccine recipients, P=0.006) and Norwalk virus infection

205 ection (82% of placebo recipients vs. 61% of vaccine recipients, P=0.05).

206 Lower mucosal VL was observed among vaccine recipients, primarily in semen (P = .04).

207 Using sera from HCMV+ glycoprotein B/MF59 vaccine recipients prior to transplant, we investigated

208 ction is all-or-nothing (ie, a proportion of vaccine recipients receive complete protection [VE] and

209 Vaccine recipients received 3 intramuscular injections o

210 Vaccine recipients received ALVAC-HIV (vCP2438) alone at

211 ing and not receiving HAART, and second-time vaccine recipients receiving HAART.

212 ents and 37 (36.6%, 27.3-46.8) of 101 rabies-vaccine recipients (relative risk 1.1, 95% CI 0.8-1.6).

213 Overall, 48.5% and 30.9% of RSV vaccine recipients reported local and systemic solicited

214 A total of 977 (56.6%) of the vaccine recipients reporting local side effects were age

215 19 (48%) of 40 vaccine recipients required cytomegalovirus-specific ant

216 4.2 per 100 patient-years in the placebo and vaccine recipients, respectively (P =.58).

217 clade B strains were seen in 10% and 15% of vaccine recipients, respectively, but responses against

218 lizing titers from convalescent patients and vaccine recipients, respectively.

219 T8 and LumSyn were observed in 84 and 93% of vaccine recipients, respectively.

220 after initial immunization in 90% and 25% of vaccine recipients, respectively.

221 Human vaccine recipients responded to the peptide sequences id

222 ere compared with vaccine-induced responses, vaccine recipient responses were > or =1 log lower, whic

223 systemic CD8(+) CTL clones established in 1 vaccine recipient revealed similar Env-specific response

224 At 28 days, >=94% of vaccine recipients seroresponded (ZEBOV-GP ELISA, >=2-fo

225 apid tests, and Western blots) and result in vaccine recipients' serum being identified as reactive a

226 Canarypox or vaccinia vaccine recipients' serum with or without HIV envelope g

227 increase in stool rotavirus IgA, whereas 31 vaccine recipients showed an increase after at least 1 d

228 groups, at 7 days postboost, at least 86% of vaccine recipients showed Ebola-specific T-cell response

229 rmed detailed assessment of an HIV-1 gag DNA vaccine recipient (subject 00015) who was previously uni

230 ent infection or disease between placebo and vaccine recipients, suggesting that antibody titers are

231 B4 genotype "supergroup" HCMV variants among vaccine recipients, suggesting that the gB1 genotype vac

232 Infection with gB1 genotype in vaccine recipients suggests a lack of strain-specific pr

233 ence of infection with ALV-E or EAV in 43 YF vaccine recipients suggests low risks for transmission o

234 the responses were broadly specific and each vaccine recipient targeted at least nine epitopes on HIV

235 Vaccine recipients tended to have broader, more robust,

236 Cellular responses were observed in 57% of vaccine recipients tested and were CD4 predominant.

237 y injection site pain) were more frequent in vaccine recipients than controls; SE frequency was simil

238 s to the vaccine sequence for sequences from vaccine recipients than from placebo recipients.

239 occus were significantly higher in conjugate vaccine recipients than in polysaccharide vaccine recipi

240 1.351 variant in serum samples obtained from vaccine recipients than in samples from placebo recipien

241 ccine regimen was a follow-up boost of RV144 vaccine recipients that occurred 6 to 8 years after the

242 bodies were of low avidity, whereas in H-DNA vaccine recipients, the antibodies were of high avidity.

243 btained in an observer-blind manner, and the vaccine recipient, their parent or carer, the funder, an

244 Among H. pylori seropositive vaccine recipients, there were no significant associatio

245 le the antibody (Ab) repertoire of protected vaccine recipients, using recombinant phages encoding ra

246 ough infections occur in partially protected vaccine recipients, vaccination likely contributes to ea

247 18 of 107 placebo recipients and two of 108 vaccine recipients (vaccine efficacy 89.0% [95% CI 65.4-

248 ter inoculation, herpes zoster occurred in 7 vaccine recipients versus 24 placebo recipients.

249 ised dropout rate (7.7% [95% CI 6.2-9.5] for vaccine recipients vs 8.8% [7.1-10.7] for placebo recipi

250 n of CVD 103-HgR compared to baseline) among vaccine recipients was 56%.

251 vaccine effectiveness among ChAdOx1 nCoV-19 vaccine recipients was 58% (95% CI, 23 to 77) - consider

252 s (VE), and a self-controlled case series of vaccine recipients was included to estimate vaccine-asso

253 1 of 10 study sites, from 37 placebo and 37 vaccine recipients was measured.

254 double-blind study of 162 HIV-negative RV144 vaccine recipients, we evaluated 2 additional boosts, gi

255 comparing viral sequences of placebo versus vaccine recipients, we found that viral sequences from v

256 n of a rich set of data collected from RV144 vaccine recipients, we here employ machine learning meth

257 adjuvanted and unadjuvanted inactivated H5N1 vaccine recipients, we identified differentially express

258 -specific binding antibody response rates in vaccine recipients were 99% for the 14-day regimen (geom

259 Only 17% of the vaccine recipients were able to generate an increase in

260 The viral burdens in the infected rgp120 vaccine recipients were also determined, and they were f

261 Serum antibodies from these human vaccine recipients were also found to be preferentially

262 Thirty-nine vaccine recipients were assessed at study entry; on the

263 ation (day 26-30) serum specimens from 80 VV vaccine recipients were examined for immunoglobulin G an

264 d not receive a booster dose; 67 of 75 study vaccine recipients were followed up at 8 months.

265 Overall 74/93 (80%) vaccine recipients were H. pylori IgG seropositive at ba

266 mples had multiple virus strains, and 50% of vaccine recipients were infected with gB1 genotype (vacc

267 re more likely to seroconvert (P = .002) and vaccine recipients were less likely to seroconvert (P =

268 Vaccine recipients were more likely than placebo recipie

269 Herpes zoster vaccine recipients were more likely to be white, women,

270 Vaccine recipients were more likely to experience runny

271 Most 1-dose vaccine recipients were protected against severe disease

272 Protected vaccine recipients were rechallenged 5 months later.

273 37 (38.6%) Gardasil and 730 (30.3%) Cervarix vaccine recipients were retrieved from the Finnish Mater

274 Serum samples from 30 vaccine recipients were selected based upon relative enz

275 All vaccine recipients were sero-positive.

276 Primary vaccine recipients were significantly more likely to hav

277 Primary vaccine recipients were significantly more likely to hav

278 Vaccine recipients were stratified by sex, race, and hig

279 ks of transmission, serum samples from 43 YF vaccine recipients were studied.

280 Overall, 490 serum specimens from 461 vaccine recipients were tested; 100 (20.4%) reacted on a

281 There was one death in a GBS-vaccine recipient, which too was unrelated to vaccinatio

282 of 75-microg vaccine, and 67% of 135-microg vaccine recipients, while responses to B were seen in 4%

283 elated with decreased viral load setpoint in vaccine recipients who acquired HIV-1.

284 OspA-vaccine recipients who acquired Lyme disease had signifi

285 vity did not seem to affect viral control in vaccine recipients who became infected, we identified se

286 Scarification and intradermal vaccine recipients who developed cutaneous pox lesions h

287 lted in increased morbidity and mortality in vaccine recipients who subsequently contracted RSV.

288 rase chain reaction and sequence analysis in vaccine recipients who tested positive for anti-HBc and/

289 tion risk by Fc effector functions, and that vaccine recipients with a specific FcgammaRIIa single-nu

290 of delayed and repetitive boosting of RV144 vaccine recipients with AIDSVAX B/E on the C1C2-specific

291 through to the end of follow-up, contrasting vaccine recipients with different values of the immune r

292 Finally, we observed that vaccine recipients with high HLA-I-associated adaptation

293 Along those lines, vaccine recipients with higher HLA-I adaptation to the G

294 versely correlated with risk of infection in vaccine recipients with low IgA; therefore, we hypothesi

295 ity and polyfunctionality scores relative to vaccine recipients with no late boost (all adjusted p<0.

296 levels against gp70 V1V2 relative to group 1 vaccine recipients with no late boost (gp70 V1V2 92TH023

297 omic variation among specimens obtained from vaccine recipients with postvaccination rash or herpes z

298 Secondary transmission of Oka VZV from vaccine recipients with postvaccination vesicular rashes

299 ethal complication that develops in smallpox vaccine recipients with severely impaired cellular immun

300 , we saw that strains isolated from infected vaccine recipients would likely be poorly cross-recogniz